Madrigal Pharmaceuticals
MDGL
135 hedge funds and large institutions have $763M invested in Madrigal Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 20 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 32
1.54% less ownership
Funds ownership: 70.21% → 68.67% (-1.5%)
2% less funds holding
Funds holding: 138 → 135 (-3)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
11% less capital invested
Capital invested by funds: $858M → $763M (-$95.1M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
39% less call options, than puts
Call options by funds: $19.2M | Put options by funds: $31.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$9.82M |
| 2 |
AC
Armistice Capital
New York
|
+$9.45M |
| 3 |
Goldman Sachs
New York
|
+$8.88M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.64M |
| 5 |
Janus Henderson Group
London,
|
+$6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$64.8M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$8.57M |
| 3 |
Jennison Associates
New York
|
-$4.79M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$4.45M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.53M |
MDGL Hedge Fund Activity: Q3 2022 in Review
135 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2022, worth a combined $763M — down 11% from $858M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of MDGL and 18 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 54 added.
The largest buyer was State Street, adding an estimated $9.82M. The largest seller was Deep Track Capital, exiting entirely with an estimated $64.8M sold.
- 135 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2022, down from 138 in Q2 2022.
- Funds reported $763M of Madrigal Pharmaceuticals stock for Q3 2022, down 11% quarter-over-quarter.
- 18 funds opened new Madrigal Pharmaceuticals positions in Q3 2022 and 20 closed out, a net change of -2 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2022 was State Street, an estimated $9.82M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2022 was Deep Track Capital, an estimated $64.8M sold.
Based on aggregated 13F filings for Q3 2022.